{"id":40168,"date":"1999-07-01T12:01:00","date_gmt":"1999-07-01T10:01:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/1999\/unerwuenschte-wirkungen-von-zytostatika"},"modified":"1999-07-01T12:01:00","modified_gmt":"1999-07-01T10:01:00","slug":"unerwuenschte-wirkungen-von-zytostatika","status":"publish","type":"post","link":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/unerwuenschte-wirkungen-von-zytostatika\/","title":{"rendered":"Unerw\u00fcnschte Wirkungen von Zytostatika"},"content":{"rendered":"<p>(Fortsetzung unseres Hauptartikels AMB 1999, 33, 41)<\/p>\n<p><b>Tabelle 2C<\/b><\/p>\n<p><b>Sp\u00e4tsch\u00e4den von Zytostatika (Monate bis Jahre nach Applikation)<\/b><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/1999\/07\/Abbildung-1999-52-1.gif\" alt=\"Abbildung 1999-52-1.gif\" class=\"table-figure\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>(Fortsetzung unseres Hauptartikels AMB 1999, 33, 41) Tabelle 2C Sp\u00e4tsch\u00e4den von Zytostatika (Monate bis Jahre nach Applikation)<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","footnotes":""},"categories":[1],"tags":[3859,1891,2551,2528,2231,4297,4356,1886,1885,635,4464,2545,2464,2385,1889,1693,4616,2549,2552,1888,502,2553,503,4916,2386,2241,2115,2527,5322,5417,5657,1894,376,1887,2530,679,6335,6336,179,6399,2543,6820,6849,6852,6905,7049,7050,7052,7055,301,642],"class_list":["post-40168","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-2-chlordesoxyadenosin","tag-5-fluorouracil","tag-alkylanzien","tag-anthrazykline","tag-bendamustin","tag-bleomycin","tag-busulfan","tag-carboplatin","tag-carmustin","tag-chemotherapie","tag-chlorambucil","tag-cisplatin","tag-cladribin","tag-cyclophosphamid","tag-cytarabin","tag-dacarbazin","tag-dactinomycin","tag-daunorubicin","tag-docetaxel","tag-doxorubicin","tag-emesis","tag-epirubicin","tag-erbrechen","tag-etoposid","tag-fludarabin","tag-gemcitabin","tag-hydroxycarbamid","tag-idarubicin","tag-ifosfamid","tag-irinotecan","tag-lomustin","tag-melphalan","tag-methotrexat","tag-mitomycin","tag-mitoxantron","tag-paclitaxel","tag-procarbacin","tag-procarbazin","tag-purin-analoga","tag-pyrimidin-analoga","tag-taxane","tag-teniposid","tag-thioguanin","tag-thiotepa","tag-topotecan","tag-vinblastin","tag-vinca-alkaloide","tag-vincristin","tag-vinorelbin","tag-zytostatika","tag-zytostatische-therapie"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Unerw\u00fcnschte Wirkungen von Zytostatika - Der Arzneimittelbrief<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/unerwuenschte-wirkungen-von-zytostatika\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Unerw\u00fcnschte Wirkungen von Zytostatika - Der Arzneimittelbrief\" \/>\n<meta property=\"og:description\" content=\"(Fortsetzung unseres Hauptartikels AMB 1999, 33, 41) Tabelle 2C Sp\u00e4tsch\u00e4den von Zytostatika (Monate bis Jahre nach Applikation)\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/unerwuenschte-wirkungen-von-zytostatika\/\" \/>\n<meta property=\"og:site_name\" content=\"Der Arzneimittelbrief\" \/>\n<meta property=\"article:publisher\" content=\"http:\/\/www.facebook.com\/derarzneimittelbrief.de\" \/>\n<meta property=\"article:published_time\" content=\"1999-07-01T10:01:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/1999\/07\/Abbildung-1999-52-1.gif\" \/>\n<meta name=\"author\" content=\"Dennis Hoppe\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dennis Hoppe\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/unerwuenschte-wirkungen-von-zytostatika\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/unerwuenschte-wirkungen-von-zytostatika\\\/\"},\"author\":{\"name\":\"Dennis Hoppe\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a04aadd6db7c06c7464bdbbb5396ed16\"},\"headline\":\"Unerw\u00fcnschte Wirkungen von Zytostatika\",\"datePublished\":\"1999-07-01T10:01:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/unerwuenschte-wirkungen-von-zytostatika\\\/\"},\"wordCount\":21,\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/unerwuenschte-wirkungen-von-zytostatika\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/1999\\\/07\\\/Abbildung-1999-52-1.gif\",\"keywords\":[\"2-Chlordesoxyadenosin\",\"5-Fluorouracil\",\"Alkylanzien\",\"Anthrazykline\",\"Bendamustin\",\"Bleomycin\",\"Busulfan\",\"Carboplatin\",\"Carmustin\",\"Chemotherapie\",\"Chlorambucil\",\"Cisplatin\",\"Cladribin\",\"Cyclophosphamid\",\"Cytarabin\",\"Dacarbazin\",\"Dactinomycin\",\"Daunorubicin\",\"Docetaxel\",\"Doxorubicin\",\"Emesis\",\"Epirubicin\",\"Erbrechen\",\"Etoposid\",\"Fludarabin\",\"Gemcitabin\",\"Hydroxycarbamid\",\"Idarubicin\",\"Ifosfamid\",\"Irinotecan\",\"Lomustin\",\"Melphalan\",\"Methotrexat\",\"Mitomycin\",\"Mitoxantron\",\"Paclitaxel\",\"Procarbacin\",\"Procarbazin\",\"Purin-Analoga\",\"Pyrimidin-Analoga\",\"Taxane\",\"Teniposid\",\"Thioguanin\",\"Thiotepa\",\"Topotecan\",\"Vinblastin\",\"Vinca-Alkaloide\",\"Vincristin\",\"Vinorelbin\",\"Zytostatika\",\"Zytostatische Therapie\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/unerwuenschte-wirkungen-von-zytostatika\\\/\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/unerwuenschte-wirkungen-von-zytostatika\\\/\",\"name\":\"Unerw\u00fcnschte Wirkungen von Zytostatika - Der Arzneimittelbrief\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/unerwuenschte-wirkungen-von-zytostatika\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/unerwuenschte-wirkungen-von-zytostatika\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/1999\\\/07\\\/Abbildung-1999-52-1.gif\",\"datePublished\":\"1999-07-01T10:01:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a04aadd6db7c06c7464bdbbb5396ed16\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/unerwuenschte-wirkungen-von-zytostatika\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/unerwuenschte-wirkungen-von-zytostatika\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/unerwuenschte-wirkungen-von-zytostatika\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/1999\\\/07\\\/Abbildung-1999-52-1.gif\",\"contentUrl\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/1999\\\/07\\\/Abbildung-1999-52-1.gif\",\"width\":500,\"height\":753},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/unerwuenschte-wirkungen-von-zytostatika\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Unerw\u00fcnschte Wirkungen von Zytostatika\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\",\"name\":\"Der Arzneimittelbrief\",\"description\":\"Unabh\u00e4ngige Arzneimittelinformationen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a04aadd6db7c06c7464bdbbb5396ed16\",\"name\":\"Dennis Hoppe\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g\",\"caption\":\"Dennis Hoppe\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Unerw\u00fcnschte Wirkungen von Zytostatika - Der Arzneimittelbrief","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/unerwuenschte-wirkungen-von-zytostatika\/","og_locale":"de_DE","og_type":"article","og_title":"Unerw\u00fcnschte Wirkungen von Zytostatika - Der Arzneimittelbrief","og_description":"(Fortsetzung unseres Hauptartikels AMB 1999, 33, 41) Tabelle 2C Sp\u00e4tsch\u00e4den von Zytostatika (Monate bis Jahre nach Applikation)","og_url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/unerwuenschte-wirkungen-von-zytostatika\/","og_site_name":"Der Arzneimittelbrief","article_publisher":"http:\/\/www.facebook.com\/derarzneimittelbrief.de","article_published_time":"1999-07-01T10:01:00+00:00","og_image":[{"url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/1999\/07\/Abbildung-1999-52-1.gif","type":"","width":"","height":""}],"author":"Dennis Hoppe","twitter_misc":{"Verfasst von":"Dennis Hoppe"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/unerwuenschte-wirkungen-von-zytostatika\/#article","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/unerwuenschte-wirkungen-von-zytostatika\/"},"author":{"name":"Dennis Hoppe","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a04aadd6db7c06c7464bdbbb5396ed16"},"headline":"Unerw\u00fcnschte Wirkungen von Zytostatika","datePublished":"1999-07-01T10:01:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/unerwuenschte-wirkungen-von-zytostatika\/"},"wordCount":21,"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/unerwuenschte-wirkungen-von-zytostatika\/#primaryimage"},"thumbnailUrl":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/1999\/07\/Abbildung-1999-52-1.gif","keywords":["2-Chlordesoxyadenosin","5-Fluorouracil","Alkylanzien","Anthrazykline","Bendamustin","Bleomycin","Busulfan","Carboplatin","Carmustin","Chemotherapie","Chlorambucil","Cisplatin","Cladribin","Cyclophosphamid","Cytarabin","Dacarbazin","Dactinomycin","Daunorubicin","Docetaxel","Doxorubicin","Emesis","Epirubicin","Erbrechen","Etoposid","Fludarabin","Gemcitabin","Hydroxycarbamid","Idarubicin","Ifosfamid","Irinotecan","Lomustin","Melphalan","Methotrexat","Mitomycin","Mitoxantron","Paclitaxel","Procarbacin","Procarbazin","Purin-Analoga","Pyrimidin-Analoga","Taxane","Teniposid","Thioguanin","Thiotepa","Topotecan","Vinblastin","Vinca-Alkaloide","Vincristin","Vinorelbin","Zytostatika","Zytostatische Therapie"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/unerwuenschte-wirkungen-von-zytostatika\/","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/unerwuenschte-wirkungen-von-zytostatika\/","name":"Unerw\u00fcnschte Wirkungen von Zytostatika - Der Arzneimittelbrief","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/unerwuenschte-wirkungen-von-zytostatika\/#primaryimage"},"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/unerwuenschte-wirkungen-von-zytostatika\/#primaryimage"},"thumbnailUrl":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/1999\/07\/Abbildung-1999-52-1.gif","datePublished":"1999-07-01T10:01:00+00:00","author":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a04aadd6db7c06c7464bdbbb5396ed16"},"breadcrumb":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/unerwuenschte-wirkungen-von-zytostatika\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/unerwuenschte-wirkungen-von-zytostatika\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/unerwuenschte-wirkungen-von-zytostatika\/#primaryimage","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/1999\/07\/Abbildung-1999-52-1.gif","contentUrl":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/1999\/07\/Abbildung-1999-52-1.gif","width":500,"height":753},{"@type":"BreadcrumbList","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/unerwuenschte-wirkungen-von-zytostatika\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/"},{"@type":"ListItem","position":2,"name":"Unerw\u00fcnschte Wirkungen von Zytostatika"}]},{"@type":"WebSite","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/","name":"Der Arzneimittelbrief","description":"Unabh\u00e4ngige Arzneimittelinformationen","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Person","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a04aadd6db7c06c7464bdbbb5396ed16","name":"Dennis Hoppe","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g","caption":"Dennis Hoppe"}}]}},"_links":{"self":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-json\/wp\/v2\/posts\/40168","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-json\/wp\/v2\/comments?post=40168"}],"version-history":[{"count":0,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-json\/wp\/v2\/posts\/40168\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-json\/wp\/v2\/media?parent=40168"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-json\/wp\/v2\/categories?post=40168"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-json\/wp\/v2\/tags?post=40168"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}